Benjamin F. Edwards & Company, Inc. Cassava Sciences Inc Transaction History
Benjamin F. Edwards & Company, Inc.
- $5.69 Billion
- Q2 2024
A detailed history of Benjamin F. Edwards & Company, Inc. transactions in Cassava Sciences Inc stock. As of the latest transaction made, Benjamin F. Edwards & Company, Inc. holds 934 shares of SAVA stock, worth $2,661. This represents 0.0% of its overall portfolio holdings.
Number of Shares
934
Previous 153
510.46%
Holding current value
$2,661
Previous $3,000
300.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding SAVA
# of Institutions
207Shares Held
14MCall Options Held
2.98MPut Options Held
6.57M-
Black Rock Inc. New York, NY3.22MShares$9.18 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.52MShares$7.19 Million0.0% of portfolio
-
State Street Corp Boston, MA1.16MShares$3.31 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA1.01MShares$2.87 Million0.0% of portfolio
-
Gallacher Capital Management LLC Lone Tree, CO580KShares$1.65 Million7.83% of portfolio
About CASSAVA SCIENCES INC
- Ticker SAVA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 40,097,900
- Market Cap $114M
- Description
- Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's...